Last reviewed · How we verify

Palonosetron (Group P)

University of Malaya · FDA-approved active Small molecule

Palonosetron (Group P) is a 5-HT3 receptor antagonist Small molecule drug developed by University of Malaya. It is currently FDA-approved for Chemotherapy-induced nausea and vomiting (CINV) prevention, Post-operative nausea and vomiting (PONV) prevention. Also known as: antiemetic.

Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.

Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention, Post-operative nausea and vomiting (PONV) prevention.

At a glance

Generic namePalonosetron (Group P)
Also known asantiemetic
SponsorUniversity of Malaya
Drug class5-HT3 receptor antagonist
Target5-HT3 receptor
ModalitySmall molecule
Therapeutic areaOncology, Gastroenterology
PhaseFDA-approved

Mechanism of action

Palonosetron binds with high affinity and selectivity to 5-hydroxytryptamine type 3 (5-HT3) receptors, which are located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By antagonizing these receptors, it prevents the emetic signal cascade triggered by chemotherapy, radiation, or post-operative conditions. It has a longer half-life and greater receptor binding affinity compared to earlier-generation 5-HT3 antagonists.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Palonosetron (Group P)

What is Palonosetron (Group P)?

Palonosetron (Group P) is a 5-HT3 receptor antagonist drug developed by University of Malaya, indicated for Chemotherapy-induced nausea and vomiting (CINV) prevention, Post-operative nausea and vomiting (PONV) prevention.

How does Palonosetron (Group P) work?

Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.

What is Palonosetron (Group P) used for?

Palonosetron (Group P) is indicated for Chemotherapy-induced nausea and vomiting (CINV) prevention, Post-operative nausea and vomiting (PONV) prevention.

Who makes Palonosetron (Group P)?

Palonosetron (Group P) is developed and marketed by University of Malaya (see full University of Malaya pipeline at /company/university-of-malaya).

Is Palonosetron (Group P) also known as anything else?

Palonosetron (Group P) is also known as antiemetic.

What drug class is Palonosetron (Group P) in?

Palonosetron (Group P) belongs to the 5-HT3 receptor antagonist class. See all 5-HT3 receptor antagonist drugs at /class/5-ht3-receptor-antagonist.

What development phase is Palonosetron (Group P) in?

Palonosetron (Group P) is FDA-approved (marketed).

What are the side effects of Palonosetron (Group P)?

Common side effects of Palonosetron (Group P) include Headache, Constipation, Diarrhea, Dizziness, Fatigue.

What does Palonosetron (Group P) target?

Palonosetron (Group P) targets 5-HT3 receptor and is a 5-HT3 receptor antagonist.

Related